Details of the Drug Combinations

General Information of This Drug (ID: DM3G74J)

Drug Name

Tamibarotene DM3G74J

Synonyms

Tamibarotene (oral, Alzheimer's disease)

Indication

Disease Entry	ICD 11	Status	REF
T-cell leukaemia	2A90	Phase 3	[1]
Alzheimer disease	8A20	Phase 2/3	[2]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

3 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Tamibarotene + Venetoclax	DC0T79H	Venetoclax	Acute Myeloid Leukemia	[3]
Tamibarotene + Azacitidine	DCQ65TW	Azacitidine	Acute Myeloid Leukemia	[4]
Tamibarotene + Azacitidine	DCIEAN8	Azacitidine	Myelodysplastic Syndromes	[1]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04797780) SY-1425 Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome. U.S. National Institutes of Health.
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2648).
3	ClinicalTrials.gov (NCT04905407) Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed AML
4	ClinicalTrials.gov (NCT02807558) A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome